The Barricaid team is proud to be ranked among the top 20 private medtech companies to watch in 2020 by MDDI (Medical Device and Diagnostic Industry). To our mission, we stay committed to reducing needless suffering by ensuring Barricaid Annular Closure is accessible to patients and surgeons.

Intrinsic Therapeutics’ Barricaid device is the only FDA PMA-approved annular closure implant. Studies have shown that annular closure may be a good option for certain patients. Barricaid is backed by substantial clinical evidence, including a Level 1 randomized, controlled trial.

See original news